Phase IV-Cervical Dystonia-INTEREST IN CD2 (INTEREST_INCD2)

This study is currently recruiting participants.
Verified February 2014 by Ipsen
Information provided by (Responsible Party):
Ipsen Identifier:
First received: December 17, 2012
Last updated: February 26, 2014
Last verified: February 2014

The purpose of the study is to document long-term response in real-life practice after injection cycles with BoNT-A in subjects suffering from idiopathic cervical dystonia (Long-term clinical and pharmaco-economic data).

Condition Intervention
Cervical Dystonia
Drug: BoNT-A injections, 3-4 times yearly

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: An International Observational Prospective Study On Long-Term Response To Botulinum Toxin Type A (BoNT-A) Injections In Subjects Suffering From Idiopathic Cervical Dystonia (CD) - Pharmaco-Economic Impact

Resource links provided by NLM:

Further study details as provided by Ipsen:

Primary Outcome Measures:
  • Change in subject's satisfaction using a 5-point Likert scale. [ Time Frame: Baseline and at every 3 to 4 months, up to 3 years. ] [ Designated as safety issue: No ]
    Identification of prognostic factors for subject's satisfaction regarding control of symptoms associated with idiopathic CD.

Secondary Outcome Measures:
  • Change from baseline in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total score and severity sub-scale. [ Time Frame: Baseline and at every 3 to 4 months, up to 3 years. ] [ Designated as safety issue: No ]
    Assessment of severity of CD.

  • Change in tremor associated with CD using Tsui score [ Time Frame: Baseline and at every 3 to 4 months, up to 3 years. ] [ Designated as safety issue: No ]
  • Change in pain relief assessed using the TWSTRS pain sub-scale. [ Time Frame: Baseline and at every 3 to 4 months, up to 3 years. ] [ Designated as safety issue: No ]
  • Change in disability will be measured with the TWSTRS disability sub-scale. [ Time Frame: Baseline and at every 3 to 4 months, up to 3 years. ] [ Designated as safety issue: No ]
  • Pharmaco-economic endpoints [ Time Frame: Baseline and at every 3 to 4 months, up to 3 years. ] [ Designated as safety issue: No ]
    • Time intervals between injections
    • Changes in concomitant treatments for CD and associated symptoms.
    • Changes in employment status

Estimated Enrollment: 1050
Study Start Date: December 2012
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Idiopathic cervical dystonia
Adults subjects from Hospitals, Private Practices suffering idiopathic cervical dystonia.
Drug: BoNT-A injections, 3-4 times yearly


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Adult subjects from Hospitals, Private Practices suffering idiopathic cervical dystonia.


Inclusion Criteria:

  • Subject for whom there is an intention to treat with BoNT-A.
  • BoNT treatment naïve or previously treated with BoNT.
  • If previously treated with BoNT, at least a 12-week interval between the last injection (BoNT-A or BoNT-B) and inclusion.
  • Subject able to comply with the protocol.
  • Provision of written informed consent prior to collect the data.

Exclusion Criteria:

  • Contraindications to any BoNT-A preparations.
  • The subject has already been included in the study.
  Contacts and Locations
Please refer to this study by its identifier: NCT01753349

Contact: Ipsen Recruitment Enquiries

  Show 107 Study Locations
Sponsors and Collaborators
Study Director: Savary Om, M.D. Ipsen
  More Information

No publications provided

Responsible Party: Ipsen Identifier: NCT01753349     History of Changes
Other Study ID Numbers: Y-79-52120-166
Study First Received: December 17, 2012
Last Updated: February 26, 2014
Health Authority: Australia: Human Research Ethics Committee
Austria: Ethikkommission
Austria: Agency for Health and Food Safety
Belgium: Ethics Committee
China: Ethics Committee
Estonia: Research Ethics Committee
France: French Data Protection Authority
Germany: Ethics Commission
Germany: Federal Institute for Drugs and Medical Devices
Hungary: Institutional Ethics Committee
Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines
Italy: Ethics Committee
Latvia: Institutional Review Board
Latvia: State Agency of Medicines
Romania: Ethics Committee
Romania: National Agency for Medicines and Medical Devices
Russia: Ethics Committee
Slovenia: Ethics Committee
Slovenia: Agency for Medicinal Products - Ministry of Health
Sweden: Institutional Review Board
United Kingdom: Research Ethics Committee
Czech Republic: Ethics Committee
Czech Republic: State Institute for Drug Control
Lebanon: Ministry of Public Health
Poland: Ethics Committee
Malaysia: Institutional Review Board
Turkey: Ethics Committee
Taiwan: Institutional Review Board
Mexico: Federal Commission for Protection Against Health Risks
Mexico: Ethics Committee
Portugal: Health Ethic Committee
Portugal: Data Protection Agency
Serbia: Ethics Committee
Spain: Ethics Committee
Spain: Local Regulatory Authority ("Comunidad Autónoma")
Brazil: Ethics Committee
Egypt: Ministry of Health, Drug Policy and Planning Center
Israel: Ethics Commission
Philippines: Ethics Committee
Philippines : Food and Drug Administration
Singapore: Health Sciences Authority
Singapore: Institutional Review Board
Thailand: Ethical Committee
United States: Institutional Review Board

Additional relevant MeSH terms:
Dystonic Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Movement Disorders
Central Nervous System Diseases
Botulinum Toxins, Type A
Neuromuscular Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions processed this record on April 17, 2014